Samsung Biologics published a video explaining how selective intensification using N-1 perfusion enhances fed-batch productivity, achieving higher seeding density, VCD, and protein output while maintaining fed-batch.
Published
Signal category
Research & Knowledge
Quote
“In this video, Seohyeon Song, Lead Scientist and Associate Director in the MSAT USP Group at Samsung Biologics, explains how: Selective intensification — N-1 perfusion strengthens the seed train while production remains fed-batch”
— Samsung Biologics team
Company
Samsung Biologics
Innovation, passion and an unwavering dedication to find breakthrough solutions in biomedicines.
- Industry
- Pharmaceutical Manufacturing
- Location
- Songdo, KR
- Company size
- 2,551 employees
Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.
Founded 2011